Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Rheumatol Ther. 2023 doi: 10.1007/s40744-023-00576-8 Epub ahead of print
The data gathered in this post-marketing surveillance study aligned with the previously established safety profile of tofacitinib, and reports were found to have consistent safety profiles in the treatment of both patient with PsA and RA. However, the results of this study should be interpreted considering the limitations of post-marketing surveillance studies.
Identificación de Dos Subpoblaciones de Tofacitinib con Diferentes Riesgos Relativos frente a Inhibidores TNF: Un análisis del estudio abierto aleatorizado controlado ORAL Surveillance
Ann Rheum Dis. 2023 doi: 10.1136/ard-2022-223715 Epub ahead of print
Findings from a post hoc analysis of ORAL Surveillance can help guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib, based on identification of subpopulations ‘at risk’.